Literature DB >> 8499380

Efficacy of corticosteroids in reversing regression after myopic photorefractive keratectomy.

F Carones1, R Brancato, E Venturi, A Scialdone, A Bertuzzi, A Tavola.   

Abstract

Topical corticosteroids are given commonly after photorefractive keratectomy (PRK). We present six eyes treated for correction of myopia ranging between -6.00 and -8.00 D, to whom corticosteroid drops were given and then suspended. Each eye had an increase in myopia with a mean of 2.00 D (range 1.00 to 3.50 D). All were then treated with topical dexamethasone (0.1%) four times per day for at least 15 days, and all showed decreases in myopia with partial or complete recovery of the intended correction (mean: 1.625 D; range 1.00 to 3.50 D). All of these refractive variations were documented by corneal topography. In one eye, refractive and topographic variations were detected by 3 days after corticosteroid treatment was initiated and they increased for 15 days. We believe corticosteroids can modulate refractive changes after PRK.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499380

Source DB:  PubMed          Journal:  Refract Corneal Surg        ISSN: 1042-962X


  3 in total

1.  Effect of Homoharringtonine on corneal haze after excimer laser photorefractive keratectomy in rabbits.

Authors:  Mingchang Zhang; Li Wang; Yong Wang; Zhengping Ding; Caikeng Mai; Shaosong Nie; Fei Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

2.  Wound healing anomalies after excimer laser photorefractive keratectomy: correlation of clinical outcomes, corneal topography, and confocal microscopy.

Authors:  R F Steinert
Journal:  Trans Am Ophthalmol Soc       Date:  1997

3.  Spherical and aspherical photorefractive keratectomy and laser in-situ keratomileusis for moderate to high myopia: two prospective, randomized clinical trials. Summit technology PRK-LASIK study group.

Authors:  R F Steinert; P S Hersh
Journal:  Trans Am Ophthalmol Soc       Date:  1998
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.